ATEC Reports Third Quarter Financial Results – Ortho Spine News
Alphatec Holdings (ATEC) reported Q3 2026 revenue of $221M, up 13% YoY, with surgical revenue at $202M, up 14%. Adjusted EBITDA was $38M, or 17% of revenue, up 400 bps YoY. Case volumes grew 20% and new surgeon users increased 25%. The company expects full-year 2026 revenue of $862M, adjusted EBITDA of $137M, and $10M in free cash flow.
How this was made
The 30-second read
Why it matters
Q3 results show solid top-line and procedural momentum, while management explicitly attributes revenue shortfall to lower biologics attachment. The company also provides full-year 2026 revenue, adjusted EBITDA, and free cash flow expectations.
Market read
Traders can update positioning based on the disclosed Q3 operating metrics, the biologics attachment explanation, and the company’s FY2026 revenue and profitability outlook.
What to watch
Hardware growth and surgeon adoption are positive, but the outlook’s credibility depends on whether management can materially improve biologics attachment performance and sustain adjusted EBITDA margin expansion.
Background
ATEC is a spine-focused provider with a procedure-focused strategy and exposure to surgical hardware, biologics attachment, and EOS revenue.
Ticker impact
Alphatec (ATEC) reported Q3 revenue of $221M (+13% YoY) and guided FY2026 revenue to about $862M, citing weaker biologics attachment.
Likely mixed reaction, with upside bias from raised/confirmed full-year growth and EBITDA expansion, offset by the biologics attachment shortfall.
The article provides both operating momentum metrics (case volumes, surgeon adoption, hardware growth) and a specific revenue headwind (lower biologics attachment) plus full-year outlook numbers.
Market effects
Reinforces demand strength in procedure and hardware segments within spine surgery, while highlighting biologics attachment as a key swing factor for revenue translation.
Limited, primarily affects US-listed medtech/spine peers via read-across on procedure adoption and biologics attachment dynamics.
Moderate, relevant to global spine-surgery equipment and biologics attachment narratives, but the disclosure is company-specific.
Counterpoint
The headline growth may overstate underlying profitability quality if biologics attachment weakness persists, potentially capping procedural revenue translation despite strong case volumes.
Key entities
- companyAlphatec Holdings, Inc.
ATEC, spine-focused provider reporting Q3 results and FY2026 outlook, with biologics attachment identified as the key revenue headwind.
- personPat Miles
Chairman and CEO who cited lower biologics attachment as the primary reason Q3 revenue fell short of expectations.
- productOsteoAdapt (Theradaptive)
Longer-term opportunity referenced by management as part of the foundation for future procedural revenue translation.
